Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Gold and Silver Juniors, Mid-tiers and Producers -- Ignore unavailable to you. Want to Upgrade?

To: Zincman who wrote (59538)	5/16/2008 1:14:30 AM
From: The Vet	Respond to of 78431

You have to consider that cancer isn't a single disease caused by a single agent like measles or mumps, it is a name given to a whole group of conditions which have similar but not identical, pathology. Therefore a single "cure" for cancer is highly unlikely. Treatments can be targeted at specific cancers with common or similar causes but there will probably be no "magic bullet" that covers all. One company with an interesting approach to a number of cancers which have had great animal trial results is TapImmune (TPIM). Their system targets a specific deficiency in protein expression and transport that is common to a number of common cancers (but not all) and by overcoming that block, the body's own immune system then can overcome the cancer no matter where it is located or has spread to. Their main problem isn't the science or the animal trials. It's going to be getting approvals to do human trials and FDA approval on the final product. The cancers they can target are usually fatal, but the way they attack them using gene therapy delivered by a benign virus is rather too radical for the FDA.